このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Trevena 将来の成長

Future 基準チェック /06

Trevenaの収益は年間11.7%で減少すると予測されていますが、年間利益は年間2.1%で増加すると予想されています。EPS は年間24.1%で増加すると予想されています。

主要情報

2.1%

収益成長率

24.1%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	-11.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	16 May 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqCM:TRVN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-32	N/A	N/A	1
12/31/2025	9	-25	N/A	N/A	2
12/31/2024	0	-32	N/A	N/A	2
3/31/2024	3	-40	-32	-32	N/A
12/31/2023	3	-40	-33	-33	N/A
9/30/2023	3	-31	-38	-38	N/A
6/30/2023	3	-38	-39	-39	N/A
3/31/2023	0	-45	-44	-44	N/A
12/31/2022	0	-54	-52	-51	N/A
9/30/2022	0	-61	-53	-53	N/A
6/30/2022	0	-59	-54	-54	N/A
3/31/2022	0	-58	-54	-54	N/A
12/31/2021	1	-52	-50	-50	N/A
9/30/2021	1	-50	-45	-45	N/A
6/30/2021	3	-41	-36	-36	N/A
3/31/2021	3	-33	-30	-30	N/A
12/31/2020	3	-29	-21	-21	N/A
9/30/2020	3	-24	-21	-21	N/A
6/30/2020	0	-27	-25	-25	N/A
3/31/2020	0	-25	-22	-22	N/A
12/31/2019	0	-25	-24	-24	N/A
9/30/2019	0	-26	-22	-23	N/A
6/30/2019	3	-22	-20	-20	N/A
3/31/2019	6	-27	-23	-23	N/A
12/31/2018	6	-31	-26	-25	N/A
9/30/2018	6	-38	-32	-31	N/A
6/30/2018	3	-49	-41	-39	N/A
3/31/2018	N/A	-60	-56	-52	N/A
12/31/2017	N/A	-72	N/A	-71	N/A
9/30/2017	N/A	-93	N/A	-87	N/A
6/30/2017	N/A	-107	N/A	-100	N/A
3/31/2017	2	-106	N/A	-100	N/A
12/31/2016	4	-103	N/A	-92	N/A
9/30/2016	6	-82	N/A	-76	N/A
6/30/2016	8	-63	N/A	-63	N/A
3/31/2016	8	-55	N/A	-55	N/A
12/31/2015	6	-51	N/A	-40	N/A
9/30/2015	4	-48	N/A	-41	N/A
6/30/2015	3	-53	N/A	-40	N/A
3/31/2015	1	-53	N/A	-40	N/A
12/31/2014	N/A	-50	N/A	-40	N/A
9/30/2014	N/A	-43	N/A	-37	N/A
6/30/2014	N/A	-37	N/A	-33	N/A
3/31/2014	0	-30	N/A	-28	N/A
12/31/2013	0	-24	N/A	-24	N/A
9/30/2013	0	-20	N/A	-17	N/A

アナリストによる今後の成長予測

収入対貯蓄率: TRVN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TRVN今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: TRVN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: TRVNの収益は今後 3 年間で減少すると予想されています (年間-11.7% )。

高い収益成長: TRVNの収益は今後 3 年間で減少すると予測されています (年間-11.7% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: TRVNの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Trevena 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Consensus EPS estimates fall by 28%, revenue upgraded

Consensus revenue estimates increase by 725%

Price target decreased by 39% to US$17.00

Price target decreased to US$28.67

Consensus forecasts updated

Recent updates

Trevena, Inc. Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

First quarter 2024 earnings released: US$0.36 loss per share (vs US$0.81 loss in 1Q 2023)

Nasdaq Hearings Panel Grants Trevena an Extension Until August 28, 2024 to Regain Compliance with the Nasdaq Continued Listing Requirements, Including the Minimum Bid Price Requirement and Equity Standard Requirement

Trevena, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Market cap size

Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. announced that it expects to receive $1.945934 million in funding

Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 28%, revenue upgraded

Trevena, Inc. Announces Board Changes

Trevena, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Revenue and earnings growth

Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study

Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023

Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement

Trevena Receives Non-Compliance Notice From Nasdaq Stock Market

Consensus revenue estimates increase by 725%

New major risk - Market cap size

Trevena, Inc. Appoints Mark Corrigan to Board of Directors

Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study

New major risk - Market cap size

Trevena Regains Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2)

Trevena, Inc. to Report Q1, 2023 Results on May 15, 2023

Price target decreased by 39% to US$17.00

Trevena Announces Publication of OLINVYK Respiratory Physiology Study in ANESTHESIOLOGY

Trevena, Inc. Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

Trevena Regains Compliance with Nasdaq Listing Requirements

Price target decreased to US$28.67

Insufficient new directors

Trevena Announces Completion of Phase 1 Study for Trv045, Novel S1p Receptor Modulator

Trevena, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Trevena Q2 2022 Earnings Preview

Trevena, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

Trevena slides on $2M preferred stock offering

Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely

Trevena Gets an Additional 180 Days to Get Listing Compliance

Consensus revenue estimates fall by 36%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Trevena, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Trevena, Inc. Receives Notice to Cease Enrollment for TRV027 as Part of the ACTIV-4 Host Tissue Platform

Trevena, Inc. Announces Results from Pfound D Sedation, Respiratory Depression, Coma, and Death May Result from E Concomitant Use of Olinvyk

Consensus forecasts updated

Trevena, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$4.67

Insufficient new directors

Trevena, Inc. Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Trevena, Inc. Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

Trevena Offers An Enticing Risk-Reward At These Prices

Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study

Trevena: Remaining Patient After A Disappointing Q2 Earnings

Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research

Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder

Trevena, Inc. Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting

Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles

Trevena Investor Presentation - Slideshow

Trevena, Inc. Announces TRV027 Selected by NIH-Funded ACTIV Initiative for COVID-19 Trial